Lv7
4990 积分 2022-09-14 加入
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
7分钟前
待确认
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
22天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients The RESTORE-1 Randomized Clinical Trial
1个月前
已关闭
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients
1个月前
已完结
A rank-based approach to improve the efficiency of inferential seamless phase 2/3 clinical trials with dose optimization
1个月前
已完结
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
2个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
2个月前
已完结
ABCL-517 Phase III Trial of Subcutaneous Epcoritamab + R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2
2个月前
已完结
皖公网安备34019202002308
